OBSTRUCTIVE SLEEP APNEA (OSA)

20-Mark Comprehensive Answer | RGUHS ENT

1. DEFINITION

• Each apnea/hypopnea episode lasts at least 10 seconds
• Commonly accompanied by oxygen desaturation of 3-4%
• Terminated by brief, unconscious arousals from sleep

2. EPIDEMIOLOGY

• Young T et al. (1993, NEJM) - Wisconsin Sleep Cohort Study: First population-based prevalence data (Scott-Brown's Otorhinolaryngology H&N Surgery, Vol 2)
• Prevalence of severe OSA in children ~1%, peak between 3-6 years (Scott-Brown's Vol 2, Ch. 27)

3. CLASSIFICATION / SEVERITY

┌─────────────────────────────────────────────────────┐
│              AHI SEVERITY CLASSIFICATION            │
│                    (AASM Criteria)                  │
├─────────────────────┬───────────────────────────────┤
│  Normal             │  AHI < 5 events/hour           │
│  Mild OSA           │  AHI 5–14 events/hour          │
│  Moderate OSA       │  AHI 15–30 events/hour         │
│  Severe OSA         │  AHI > 30 events/hour          │
└─────────────────────┴───────────────────────────────┘

4. PATHOPHYSIOLOGY

Four Key Phenotypic Traits (Cummings, Fig. 15.1):

┌─────────────────────────────────────────────────────────────────────┐
│            PATHOPHYSIOLOGY OF OSA - FOUR PHENOTYPES                │
│                                                                     │
│  1. IMPAIRED UPPER AIRWAY ANATOMY                                  │
│     └── Narrow/collapsible pharynx                                 │
│         (obesity, soft tissue hypertrophy, retrognathia)           │
│                          ↓                                         │
│  2. INADEQUATE UPPER AIRWAY DILATOR MUSCLE RESPONSE               │
│     └── Genioglossus fails to maintain patency during sleep        │
│         (reduced neuromuscular compensation)                       │
│                          ↓                                         │
│  3. LOW AROUSAL THRESHOLD                                          │
│     └── Awakens too easily → prevents deep sleep → unstable        │
│         pharyngeal dilator response                                │
│                          ↓                                         │
│  4. HIGH LOOP GAIN (Unstable Respiratory Control)                  │
│     └── Oversensitive to CO₂ → over-ventilation → airway collapse │
│                                                                     │
│  RESULT: Repetitive pharyngeal collapse → Apnea/Hypopnea          │
└─────────────────────────────────────────────────────────────────────┘

Anatomic Sites of Obstruction (Fujita Classification):

• Type I - Retropalatal collapse only
• Type II - Both retropalatal AND retrolingual collapse
• Type III - Retrolingual collapse only

Critical Closing Pressure (Pcrit):

• OSA patients: Pcrit above atmospheric pressure
• Normal individuals: Pcrit below -5 cm H₂O
• Genioglossus is the most important airway dilator muscle

5. ETIOLOGY / RISK FACTORS

┌─────────────────────────────────────────────────────┐
│              RISK FACTORS FOR OSA                   │
├─────────────────────────────────────────────────────┤
│  MODIFIABLE          │  NON-MODIFIABLE              │
│  ─────────────────   │  ─────────────────────────── │
│  • Obesity (BMI>30)  │  • Age (>40 years)           │
│  • Alcohol use       │  • Male sex                  │
│  • Sedative use      │  • Positive family history   │
│  • Nasal congestion  │  • Craniofacial: retrognathia│
│  • Smoking           │    micrognathia              │
│  • Supine sleeping   │  • Racial: Asian patients    │
│  • Hypothyroidism    │    (smaller craniofacial)    │
│  • Acromegaly        │  • Postmenopause (females)   │
└─────────────────────┴──────────────────────────────┘

6. CLINICAL FEATURES

Nocturnal Symptoms:

• Loud snoring (most common partner complaint)
• Witnessed apnea, choking, gasping episodes
• Restless sleep, night sweats
• Nocturia, nocturnal enuresis
• Nocturnal headaches

Daytime Symptoms (Box 15.1, Cummings):

• Excessive daytime somnolence (present in ~50%)
• Morning fatigue, unrefreshing sleep
• Memory loss, decreased cognitive function
• Depression, personality changes
• Decreased libido and impotence

Physical Examination Findings (Box 15.4, Cummings):

7. DIAGNOSIS

FLOWCHART: DIAGNOSTIC APPROACH TO OSA

                    ┌──────────────────────────────────┐
                    │   CLINICAL SUSPICION OF OSA      │
                    │  (Snoring + EDS + witnessed apnea)│
                    └──────────────┬───────────────────┘
                                   │
                    ┌──────────────▼───────────────────┐
                    │       SCREENING TOOLS             │
                    │  • Epworth Sleepiness Scale (ESS) │
                    │    Score >10 = suspicious         │
                    │  • STOP-BANG Questionnaire        │
                    │    Score ≥5 = High risk           │
                    │  • Berlin Questionnaire           │
                    └──────────────┬───────────────────┘
                                   │
              ┌────────────────────┼────────────────────┐
              │                    │                    │
    ┌─────────▼──────┐   ┌─────────▼──────┐   ┌────────▼───────┐
    │  PHYSICAL EXAM │   │    FLEXIBLE     │   │  INVESTIGATIONS│
    │  BMI, BP, neck │   │  NASOENDOSCOPY │   │  CBC, TFT,     │
    │  circumference │   │  Mullär maneuver│   │  blood glucose │
    │  Mallampati score│  │  DISE          │   │  ECG           │
    └────────────────┘   └────────────────┘   └────────────────┘
                                   │
                    ┌──────────────▼───────────────────┐
                    │        POLYSOMNOGRAPHY (PSG)      │
                    │     "Gold Standard Diagnosis"     │
                    │   (In-lab or Home Sleep Apnea     │
                    │         Test - HSAT)              │
                    └──────────────┬───────────────────┘
                                   │
              ┌────────────────────┼────────────────────┐
              │                    │                    │
    ┌─────────▼──────┐   ┌─────────▼──────┐   ┌────────▼───────┐
    │   AHI < 5      │   │   AHI 5-14     │   │   AHI ≥ 15     │
    │  (Normal or    │   │  (Mild) +      │   │  (Moderate/    │
    │  re-evaluate)  │   │  symptoms/     │   │   Severe OSA)  │
    │                │   │  comorbidities │   │                │
    └────────────────┘   └────────────────┘   └────────────────┘

Epworth Sleepiness Scale (ESS):

• Score 0-10: Normal
• Score >10: Excessive daytime sleepiness - investigate for OSA

STOP-BANG Questionnaire (Box 15.2, Cummings):

• Score ≥ 3: High risk; Score 5-8: High probability of moderate-severe OSA

Polysomnography (PSG) - Gold Standard:

• AHI ≥ 5 + symptoms/comorbidities, OR
• AHI ≥ 15 (regardless of symptoms)

8. DRUG-INDUCED SLEEP ENDOSCOPY (DISE)

Fiberoptic View of Hypopharyngeal Collapse (Müller Maneuver):

9. COMPLICATIONS / CONSEQUENCES

┌──────────────────────────────────────────────────────────────┐
│           CONSEQUENCES OF UNTREATED OSA                     │
├────────────────────┬─────────────────────────────────────────┤
│  CARDIOVASCULAR    │  Systemic hypertension (most common)   │
│                    │  Pulmonary hypertension                │
│                    │  Arrhythmias (atrial fibrillation)     │
│                    │  Coronary artery disease               │
│                    │  Congestive heart failure              │
│                    │  Stroke / TIA                          │
│                    │  3× risk of fatal CV events            │
├────────────────────┼─────────────────────────────────────────┤
│  METABOLIC         │  Insulin resistance / Type 2 DM        │
│                    │  Metabolic syndrome                    │
│                    │  GERD (higher prevalence)              │
├────────────────────┼─────────────────────────────────────────┤
│  NEUROCOGNITIVE    │  Impaired attention, working memory    │
│                    │  Executive dysfunction                 │
│                    │  Depression, mood changes              │
├────────────────────┼─────────────────────────────────────────┤
│  MORTALITY         │  AI >20: 63% survival at 8 years       │
│                    │  vs 96% in treated patients            │
│                    │  2.5× risk of motor vehicle accidents  │
└────────────────────┴─────────────────────────────────────────┘

10. MANAGEMENT

FLOWCHART: MANAGEMENT OF OSA

┌────────────────────────────────────────────────────────────────┐
│                    CONFIRMED OSA ON PSG                        │
└──────────────────────────────┬─────────────────────────────────┘
                               │
            ┌──────────────────┼──────────────────┐
            │                  │                  │
   ┌────────▼────────┐  ┌──────▼──────┐  ┌───────▼───────┐
   │   MILD OSA      │  │ MODERATE    │  │  SEVERE OSA   │
   │   (AHI 5-14)    │  │    OSA      │  │  (AHI ≥ 30)   │
   │                 │  │ (AHI 15-30) │  │               │
   └────────┬────────┘  └──────┬──────┘  └───────┬───────┘
            │                  │                  │
   ┌────────▼────────┐         │         ┌───────▼───────┐
   │  Lifestyle +    │         │         │  CPAP (first  │
   │  Positional Rx  │         │         │  line) ALWAYS │
   │  ± OAT if CPAP  │         │         │               │
   │  refused        │         │         └───────┬───────┘
   └─────────────────┘  ┌──────▼──────┐          │
                        │ CPAP First  │  ┌────────▼──────┐
                        │ Line        │  │ CPAP FAILURE/ │
                        │ + Lifestyle │  │  REFUSAL?     │
                        └─────────────┘  └────────┬──────┘
                                                  │
                              ┌───────────────────┼──────────────────┐
                              │                   │                  │
                    ┌─────────▼──────┐   ┌────────▼──────┐  ┌───────▼──────┐
                    │  ORAL APPLIANCE│   │  POSITIONAL   │  │  SURGERY     │
                    │  THERAPY (OAT) │   │  THERAPY      │  │  (staged)    │
                    │  MAD/MRD       │   │               │  │              │
                    └────────────────┘   └───────────────┘  └──────────────┘

A. Lifestyle/Conservative Measures:

• Weight loss (10% weight reduction → ~26% AHI reduction)
• Avoid alcohol, sedatives, smoking
• Positional therapy (avoid supine position)
• Regular exercise

B. Non-Surgical: CPAP (Continuous Positive Airway Pressure)

• Acts as a "pneumatic splint" maintaining airway patency
• Reduces AHI, blood pressure (~10 mmHg reduction), CV events
• Improves neurocognitive function and quality of life
• Variants: Auto-CPAP (APAP), BiPAP/BPAP for complex OSA

C. Oral Appliance Therapy (OAT):

• Mandibular Advancement Device (MAD)/Mandibular Repositioning Device
• Alternative for mild-moderate OSA, CPAP-intolerant patients
• Mechanism: Protrudes mandible forward, enlarges pharyngeal airway

D. Surgical Options (Box 15.7, Cummings):

┌──────────────────────────────────────────────────────────────────┐
│                SURGICAL TREATMENT OPTIONS (STAGED)               │
├──────────────────────┬───────────────────────────────────────────┤
│  NASAL SURGERY       │  Septoplasty                             │
│                      │  Inferior turbinate reduction            │
├──────────────────────┼───────────────────────────────────────────┤
│  PALATAL SURGERY     │  UPPP (Uvulopalatopharyngoplasty)        │
│  (Retropalatal)      │  Laser-assisted UP (LAUP)               │
│                      │  Palatal implants (Pillar procedure)     │
│                      │  Lateral pharyngoplasty                 │
│                      │  Expansion sphincter pharyngoplasty     │
├──────────────────────┼───────────────────────────────────────────┤
│  TONGUE BASE /       │  Tongue base reduction (coblation,       │
│  HYPOPHARYNGEAL      │   radiofrequency)                        │
│                      │  Lingual tonsillectomy                  │
│                      │  TORS (Transoral Robotic Surgery)        │
│                      │  Genioglossus advancement               │
│                      │  Hyoid suspension (hyoidthyroidpexy)    │
├──────────────────────┼───────────────────────────────────────────┤
│  SKELETAL SURGERY    │  Maxillomandibular advancement (MMA)    │
│                      │  Distraction osteogenesis               │
├──────────────────────┼───────────────────────────────────────────┤
│  LAST RESORT         │  Tracheostomy (definitive, curative)    │
└──────────────────────┴───────────────────────────────────────────┘

• AHI >5 and <14 with symptoms or comorbidities
• AHI ≥15
• Oxyhemoglobin desaturation <90%
• Failed or refused medical therapy
• Medically stable for recommended procedure

E. Hypoglossal Nerve Stimulation (HNS):

• Implantable neurostimulator activating genioglossus and tongue muscles during sleep
• Approved for moderate-severe OSA with BMI <32, CPAP failure
• Systematic review (Alrubasy et al., Resp Med 2024, PMID 39401661): significant AHI reduction; STAR trial results sustained at long-term follow-up

11. TORS (Transoral Robotic Surgery) FOR OSA

• Allows precise lingual tonsillectomy, tongue base resection, epiglottectomy
• Multiinstitutional study (2015): 293 procedures - mean AHI decrease of 24; success rate (AHI<20 + 50% reduction) demonstrated; complication rate 20.7% but no life-threatening events
• Best results when BMI <30
• (Cummings Otolaryngology, Ch. 28)

12. SPECIAL POPULATIONS

Pediatric OSA (Scott-Brown's Vol 2, Ch. 27):

• Prevalence ~1%; peak 3-6 years, equal sex ratio
• Cause: Adenotonsillar hypertrophy (most common)
• Features: Hyperactive behaviour, poor academic performance, neurobehavioural morbidity
• Treatment: Adenotonsillectomy is first-line - results in IGF-1 rise and growth spurt
• PSG scores improve significantly post-adenoidectomy

OSA in Women (Cummings):

• Under-diagnosed due to atypical presentation
• More likely to report insomnia, palpitations, ankle edema
• Prevalence increases post-menopause

13. COMORBIDITIES

• Cardiovascular: Heart failure, systemic/pulmonary hypertension, AF, CAD, stroke
• Respiratory: COPD overlap syndrome, asthma
• Metabolic: Metabolic syndrome, Type 2 DM
• COVID-19: OSA independently increases risk of severe SARS-CoV-2 infection
• Surgical risk: Untreated severe OSA increases adverse cardiocerebrovascular events within 30 days of major non-cardiac surgery

14. PERIOPERATIVE MANAGEMENT

• Stepwise airway management algorithm
• Avoid paralytics until mask ventilation confirmed
• Oropharyngeal airway ready
• Consider awake fiberoptic intubation
• Counsel patient about possible tracheostomy
• Pre-op cardiovascular evaluation mandatory

15. RECENT ADVANCES (2024-2026)

1. Tirzepatide for OSA (SURMOUNT-OSA Trial - NEJM 2024)

• Phase 3, double-blind RCT (Malhotra A et al., NEJM 2024, PMID 38912654)
• Participants: Moderate-severe OSA + obesity (mean AHI ~51 events/hr, mean BMI ~39)
• Results:
  • Trial 1 (PAP-naive): Mean AHI reduction -25.3 events/hr with tirzepatide vs -5.3 with placebo (difference -20.0, p<0.001)
  • Trial 2 (PAP users): Mean AHI reduction -29.3 vs -5.5 (difference -23.8, p<0.001)
• Also reduced: Body weight, hypoxic burden, hsCRP, systolic BP, sleep impairment scores
• Significance: First GLP-1/GIP receptor agonist proven effective for OSA; FDA approved tirzepatide (Zepbound) for OSA in 2024

2. Bilateral HNS (2025 Clinical Trial, PMID 40702817)

• Bilateral hypoglossal nerve stimulation shown safe and effective in non-randomized clinical trial (Woodson et al., J Clin Sleep Med 2025)

3. Precision/Phenotype-Based Treatment

• Treatment tailored to individual OSA phenotype (anatomy, arousal threshold, loop gain, muscle responsiveness) - "precision medicine" approach described in Cummings (7th ed.)
• Pharmacological targeting of individual phenotypic traits under active investigation

4. Hypoglossal Nerve Stimulation Meta-Analysis (2024)

• Alrubasy et al., Respir Med 2024 (PMID 39401661) - Updated meta-analysis confirming AHI reduction and safety of HNS; Inspire device FDA approved

5. DISE-Guided Surgery

• Drug-induced sleep endoscopy now recommended to guide surgical planning; changes management in >50% of patients

6. Home Sleep Apnea Testing (HSAT)

• Validated for moderate-severe OSA diagnosis in uncomplicated patients; reduces cost and improves access to diagnosis

SUMMARY FLOWCHART: OSA - "COMPLETE PICTURE"

PREDISPOSING FACTORS
(Obesity, retrognathia, adenotonsillar hypertrophy,
 male sex, age, alcohol)
         │
         ▼
ANATOMIC NARROW PHARYNX + NEUROMUSCULAR FAILURE
         │
         ▼
PHARYNGEAL COLLAPSE DURING SLEEP
         │
         ▼
APNEA/HYPOPNEA (≥10 sec) → ↓SpO₂ → Arousal
         │
    ┌────┴────┐
    │ SLEEP   │ ← Fragmented, non-restorative sleep
    │ CYCLE   │
    │DISRUPTED│
    └────┬────┘
         │
    ┌────┴────────────────────┐
    │   CLINICAL CONSEQUENCES  │
    │  EDS, cognitive deficit   │
    │  HTN, CV disease, DM      │
    └────┬────────────────────┘
         │
    ┌────▼────────────────────────────────────┐
    │              DIAGNOSIS                  │
    │  Screening: ESS, STOP-BANG              │
    │  Confirmation: PSG (AHI) / HSAT         │
    │  Localization: DISE, Muller maneuver     │
    └────┬────────────────────────────────────┘
         │
    ┌────▼────────────────────────────────────┐
    │              TREATMENT                  │
    │  1st Line: CPAP (moderate-severe)       │
    │  Alternatives: OAT, Positional therapy  │
    │  Surgical: UPPP, MMA, TORS, HNS        │
    │  NEW: Tirzepatide (SURMOUNT-OSA, 2024) │
    └─────────────────────────────────────────┘

REFERENCES (RGUHS-Relevant Textbooks)

• Malhotra A et al. Tirzepatide for OSA and Obesity. NEJM 2024 (PMID 38912654) - SURMOUNT-OSA Phase 3 RCT
• Alrubasy WA et al. HNS for OSA - Updated Systematic Review. Resp Med 2024 (PMID 39401661)
• Woodson BT et al. Bilateral HNS for OSA. J Clin Sleep Med 2025 (PMID 40702817)
• Platon AL et al. An Update on OSAS - Literature Review. Medicina 2023 (PMID 37629749)

RGUHS Exam Tip: For 20 marks, write all sections above. For 10 marks, focus on: Definition, Classification (AHI), Pathophysiology (4 phenotypes), Diagnosis (ESS + STOP-BANG + PSG), Treatment (CPAP as first line + surgical options), and one Recent Advance (Tirzepatide/HNS). Diagrams of the STOP-BANG table, AHI classification box, and the Flowchart for Management are highly scoring.